Biopharmaceuticals: Benefits for Patients with Autoimmune Diseases

Rubrik: Arzneimittelwesen

(Treffer aus pharmind, Nr. 10, Seite 1248 (2020))

Mathias F | Bhonsle-Deeng L

Biopharmaceuticals: Benefits for Patients with Autoimmune Diseases / Targeted therapy, smart devices and patient support programs ensure patient well-being and additionally benefit society at large · Mathias F¹, Bhonsle-Deeng L² · ¹ Rentschler Biopharma SE, Laupheim und vfa bio, Berlin und Rentschler Biopharma SE, Laupheim
In 2018, immunological drugs – which include those for treating autoimmune diseases – led the market by accounting for 32 % of all revenue generated by the sale of biopharmaceuticals in Germany. Together with oncology and metabolic diseases, immunology contributed to 75 % of all revenue. Moreover, this segment demonstrated the strongest growth rate of 14 % in comparison to the previous year (in addition to oncology). Clearly, immunological drugs play a central role in the economical contribution of biopharmaceuticals in Germany. In addition to giving a boost to economy, these drugs greatly benefit patients with autoimmune diseases. They are invaluable to effective therapy ...